Biomea Fusion (BMEA) Cash from Investing Activities (2020 - 2026)
Biomea Fusion (BMEA) posted Cash from Investing Activities of $550000.0 for Q1 2026, up 770.73% sequentially from -$82000.0 in Q4 2024.
Biomea Fusion (BMEA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Cash from Investing Activities for 6 years, with the latest figure at $550000.0 in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to $550000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $550000.0 (up 268.2% YoY) and the FY2024 annual result came in at -$362000.0, up 83.69% from the prior year.
- Cash from Investing Activities advanced to $550000.0 in Q1 2026 per BMEA's latest filing, from -$82000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $20.4 million in Q1 2022 and troughed at -$1.8 million in Q1 2023.
- A 4-year average of $1.9 million and a median of -$39000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 984.56% in 2022, then tumbled 925.0% in 2024.
- Over 4 years, Cash from Investing Activities stood at -$701000.0 in 2022, then jumped by 98.86% to -$8000.0 in 2023, then sank by 925.0% to -$82000.0 in 2024, then soared by 770.73% to $550000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $550000.0, -$82000.0, and -$186000.0 for Q1 2026, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 550,000.00 |
| Mar 31, 2026 | 550,000.00 |
| Dec 31, 2024 | -82,000.00 |
| Dec 31, 2024 | -82,000.00 |
| Sep 30, 2024 | -186,000.00 |
| Sep 30, 2024 | -186,000.00 |
| Jun 30, 2024 | -59,000.00 |
| Jun 30, 2024 | -59,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Dec 31, 2023 | -8,000.00 |
| Dec 31, 2023 | -8,000.00 |
| Sep 30, 2023 | -39,000.00 |
| Sep 30, 2023 | -39,000.00 |
| Jun 30, 2023 | -417,000.00 |
| Jun 30, 2023 | -417,000.00 |
| Mar 31, 2023 | -1.76 Mn |
| Mar 31, 2023 | -1.76 Mn |
| Dec 31, 2022 | -701,000.00 |
| Dec 31, 2022 | -701,000.00 |